Replies to post #35610 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

I agree Ignatius, the cash needs will likely be met through an accretive deal, but he can't say much now until it's announced.

[Meishairwin]

Ig, I'm sure he's working to raise money through partnering deals, but that's not "news" of any meaningful kind IMHO -- that's what biotech CEO's are ALWAYS doing -- it's their core job.

I was looking for not only a program review (which could have been done in 10-15 mins), but also a financial review (for which 0 mins was allocated).

As for others on this board who think DOC is the reason for ADXS current share price, count me on the other side of that debate. ADXS share price had been bouncing around $8.50 for 6 months until the market learned he was leaving (30 days prior to his actual departure). Now it's at $4.40...almost 50% drop.

I'm with the market in its reaction to this presentation -- ADXS has dropped about 3% suggesting those following ADXS did not see anything positive in this presentation. I did not expect "blockbuster" news of any kind from Lombardo. I was hoping for a more focused and upbeat presentation around how this company will fund itself into 2020+.